Truist raised the firm’s price target on Stericycle to $57 from $50 and keeps a Hold rating on the shares. The company reported Q4 upside and issued normalized 2024 guidance, with operational efficiencies and workforce management set to drive 150bps of margin expansion to 17.5%, the analyst tells investors in a research note. Truist adds it would further “warm to the name” on improved free cash flow conversion and further demonstrated progress on targeted EBITDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SRCL:
- Stericycle reports Q4 adjusted EPS 54c, consensus 47c
- Stericycle, Inc. Reports Results For The Fourth Quarter 2023
- SRCL Earnings this Week: How Will it Perform?
- Stericycle to Present at Raymond James 45th Annual Institutional Investors Conference in March
- Stericycle price target raised to $50 from $45 at Truist